score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability	FDA-Approved			Rearrangement	NTRK2	Fusion	NTRK2--AUH			0.0	0.0		Investigate Actionability	Entrectinib	TRK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for entrectinib for adult and pediatric patients 12 years or old with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation.	Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212726s000lbl.pdf. Revised August 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212726s000lbl.pdf													0				NTRK2--AUH Fusion		Osteosarcoma-IAS513		
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						Osteosarcoma-IAS513		
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.G242R	0.1746	126.0	0.0	0.0																					0	188.0	0.2234	1.0	FIP1L1 p.G242R (Missense)		Osteosarcoma-IAS513	Osteosarcoma-IAS513-Tumor-SM-2RCB3	Osteosarcoma-IAS513-Normal-SM-2RCCI
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.S2309fs	0.5614	57.0	0.0	0.0																					0	0.0	0.0	0.0	NF1 p.S2309fs (Frameshift)		Osteosarcoma-IAS513	Osteosarcoma-IAS513-Tumor-SM-2RCB3	Osteosarcoma-IAS513-Normal-SM-2RCCI
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion)		Osteosarcoma-IAS513		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.452																									0				COSMIC Signature (version 2) 1 (45%)		Osteosarcoma-IAS513		
